Alaska Permanent Fund Corp Acquires 14,593 Shares of Perrigo Company plc (NYSE:PRGO)

Alaska Permanent Fund Corp raised its holdings in shares of Perrigo Company plc (NYSE:PRGO) by 16,773.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,680 shares of the company’s stock after purchasing an additional 14,593 shares during the period. Alaska Permanent Fund Corp’s holdings in Perrigo were worth $472,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. GAMMA Investing LLC bought a new position in shares of Perrigo in the 4th quarter worth approximately $30,000. Parkside Financial Bank & Trust raised its position in shares of Perrigo by 1,694.8% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,041 shares of the company’s stock worth $34,000 after acquiring an additional 983 shares in the last quarter. Blue Trust Inc. raised its position in shares of Perrigo by 34.5% in the 4th quarter. Blue Trust Inc. now owns 1,556 shares of the company’s stock worth $50,000 after acquiring an additional 399 shares in the last quarter. Fifth Third Bancorp raised its position in shares of Perrigo by 39.5% in the 3rd quarter. Fifth Third Bancorp now owns 1,714 shares of the company’s stock worth $55,000 after acquiring an additional 485 shares in the last quarter. Finally, Signaturefd LLC raised its position in shares of Perrigo by 25.6% in the 4th quarter. Signaturefd LLC now owns 2,240 shares of the company’s stock worth $72,000 after acquiring an additional 457 shares in the last quarter. Institutional investors own 95.91% of the company’s stock.

Perrigo Stock Performance

Shares of NYSE:PRGO opened at $31.94 on Friday. The stock has a fifty day simple moving average of $30.52 and a two-hundred day simple moving average of $30.80. Perrigo Company plc has a 12-month low of $25.77 and a 12-month high of $40.28. The company has a current ratio of 1.79, a quick ratio of 1.07 and a debt-to-equity ratio of 0.76.

Perrigo (NYSE:PRGO) last posted its earnings results on Tuesday, February 27th. The company reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. The business had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.17 billion. Perrigo had a positive return on equity of 7.34% and a negative net margin of 0.27%. The company’s quarterly revenue was up .1% compared to the same quarter last year. During the same quarter last year, the company earned $0.75 EPS. As a group, equities research analysts expect that Perrigo Company plc will post 2.55 EPS for the current fiscal year.

Perrigo Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 26th. Shareholders of record on Friday, March 8th were issued a $0.276 dividend. This is a positive change from Perrigo’s previous quarterly dividend of $0.27. The ex-dividend date was Thursday, March 7th. This represents a $1.10 dividend on an annualized basis and a dividend yield of 3.46%. Perrigo’s dividend payout ratio (DPR) is presently -1,100.00%.

Insiders Place Their Bets

In other Perrigo news, EVP Alison Ives bought 2,490 shares of Perrigo stock in a transaction on Tuesday, March 5th. The stock was acquired at an average price of $27.26 per share, with a total value of $67,877.40. Following the acquisition, the executive vice president now owns 16,122 shares in the company, valued at $439,485.72. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, EVP Alison Ives acquired 2,490 shares of the business’s stock in a transaction that occurred on Tuesday, March 5th. The stock was bought at an average price of $27.26 per share, with a total value of $67,877.40. Following the completion of the acquisition, the executive vice president now directly owns 16,122 shares of the company’s stock, valued at approximately $439,485.72. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Robert Willis acquired 6,000 shares of the business’s stock in a transaction that occurred on Thursday, February 29th. The stock was purchased at an average cost of $25.87 per share, with a total value of $155,220.00. Following the acquisition, the executive vice president now directly owns 25,105 shares of the company’s stock, valued at $649,466.35. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 17,990 shares of company stock valued at $475,227. Corporate insiders own 0.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on PRGO. Canaccord Genuity Group reiterated a “buy” rating and set a $42.00 price objective on shares of Perrigo in a research note on Friday, April 12th. JPMorgan Chase & Co. lowered their price objective on Perrigo from $48.00 to $41.00 and set an “overweight” rating for the company in a research note on Wednesday, February 28th. Piper Sandler lifted their price objective on Perrigo from $35.00 to $39.00 and gave the company an “overweight” rating in a research note on Monday, April 8th. Finally, StockNews.com upgraded Perrigo from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd.

About Perrigo

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.